FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998086095> ?p ?o ?g. }

• W1998086095 endingPage "1857" @default.
• W1998086095 startingPage "1847" @default.
• W1998086095 abstract "A nonagonist monocyte chemotactic protein-1 (MCP-1/CCL2) mutant (PA508) with increased affinity for glycosaminoglycans and thus competing with CCL2 was evaluated as a candidate for preventing neointima formation or myocardial ischemia/reperfusion injury. Myocardial infarction (MI) remains a major cause of death worldwide despite improved interventional and therapeutic options. Therefore, the discovery of drugs that limit restenosis after intervention and post-MI damage remains an important challenge. The function of PA508 was assessed in functional assays in vitro and in mouse models of wire-induced neointima formation and experimental MI. PA508 was functionally inactive in CC chemokine receptor 2 (CCR2) binding and calcium influx but inhibited monocyte chemotaxis or transendothelial migration toward CCL2, suggesting that it interferes with CCL2 presentation. In wild-type but not CCR2-deficient mice, PA508 reduced inflammatory leukocyte recruitment without affecting differential leukocyte counts, CCL2 levels, organ function, or morphology, indicating that it specifically attenuates the CCL2-CCR2 axis. Compared with vehicle, daily intraperitoneal injection of PA508 significantly (p < 0.05, n = 5) reduced neointimal plaque area and mononuclear cell infiltration in carotid arteries of hyperlipidemic apolipoprotein E-deficient mice while increasing smooth muscle cell content. In C57Bl/6J mice that underwent myocardial ischemia/reperfusion, treatment with PA508 significantly reduced infarction size, monocyte infiltration, and collagen and myofibroblast content in the infarction area and preserved heart function compared with vehicle (p < 0.05, n = 4 to 8). Here we demonstrate that administration of a rationally designed CCL2 competitor reduced inflammatory monocyte recruitment, limited neointimal hyperplasia, and attenuated myocardial ischemia/reperfusion injury in mice and could therefore be envisioned as a combined therapeutic approach for restenosis and MI." @default.
• W1998086095 created "2016-06-24" @default.
• W1998086095 creator A5001883769 @default.
• W1998086095 creator A5017294918 @default.
• W1998086095 creator A5017760830 @default.
• W1998086095 creator A5024272482 @default.
• W1998086095 creator A5030119793 @default.
• W1998086095 creator A5042156018 @default.
• W1998086095 creator A5044136579 @default.
• W1998086095 creator A5048913958 @default.
• W1998086095 creator A5072416141 @default.
• W1998086095 creator A5089227561 @default.
• W1998086095 creator A5089768561 @default.
• W1998086095 date "2010-11-01" @default.
• W1998086095 modified "2023-10-15" @default.
• W1998086095 title "A New Monocyte Chemotactic Protein-1/Chemokine CC Motif Ligand-2 Competitor Limiting Neointima Formation and Myocardial Ischemia/Reperfusion Injury in Mice" @default.
• W1998086095 cites W1486677432 @default.
• W1998086095 cites W1559783545 @default.
• W1998086095 cites W1968944419 @default.
• W1998086095 cites W1978095098 @default.
• W1998086095 cites W1987143719 @default.
• W1998086095 cites W1987767880 @default.
• W1998086095 cites W1988229704 @default.
• W1998086095 cites W1999684167 @default.
• W1998086095 cites W2002584410 @default.
• W1998086095 cites W2014092649 @default.
• W1998086095 cites W2020245957 @default.
• W1998086095 cites W2021127773 @default.
• W1998086095 cites W2032811951 @default.
• W1998086095 cites W2032901102 @default.
• W1998086095 cites W2050744280 @default.
• W1998086095 cites W2053577903 @default.
• W1998086095 cites W2055600725 @default.
• W1998086095 cites W2058054323 @default.
• W1998086095 cites W2058189238 @default.
• W1998086095 cites W2059845506 @default.
• W1998086095 cites W2062764413 @default.
• W1998086095 cites W2064193713 @default.
• W1998086095 cites W2068076840 @default.
• W1998086095 cites W2070530677 @default.
• W1998086095 cites W2082265631 @default.
• W1998086095 cites W2089732611 @default.
• W1998086095 cites W2090687004 @default.
• W1998086095 cites W2092377922 @default.
• W1998086095 cites W2092869368 @default.
• W1998086095 cites W2101444839 @default.
• W1998086095 cites W2106557745 @default.
• W1998086095 cites W2109906269 @default.
• W1998086095 cites W2111194166 @default.
• W1998086095 cites W2118920330 @default.
• W1998086095 cites W2121831499 @default.
• W1998086095 cites W2125600524 @default.
• W1998086095 cites W2134996862 @default.
• W1998086095 cites W2138025229 @default.
• W1998086095 cites W2141299792 @default.
• W1998086095 cites W2141911926 @default.
• W1998086095 cites W2144948248 @default.
• W1998086095 cites W2146936491 @default.
• W1998086095 cites W2165984084 @default.
• W1998086095 cites W2166118117 @default.
• W1998086095 doi "https://doi.org/10.1016/j.jacc.2010.04.066" @default.
• W1998086095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21087715" @default.
• W1998086095 hasPublicationYear "2010" @default.
• W1998086095 type Work @default.
• W1998086095 sameAs 1998086095 @default.
• W1998086095 citedByCount "100" @default.
• W1998086095 countsByYear W19980860952012 @default.
• W1998086095 countsByYear W19980860952013 @default.
• W1998086095 countsByYear W19980860952014 @default.
• W1998086095 countsByYear W19980860952015 @default.
• W1998086095 countsByYear W19980860952016 @default.
• W1998086095 countsByYear W19980860952017 @default.
• W1998086095 countsByYear W19980860952018 @default.
• W1998086095 countsByYear W19980860952019 @default.
• W1998086095 countsByYear W19980860952020 @default.
• W1998086095 countsByYear W19980860952021 @default.
• W1998086095 countsByYear W19980860952022 @default.
• W1998086095 countsByYear W19980860952023 @default.
• W1998086095 crossrefType "journal-article" @default.
• W1998086095 hasAuthorship W1998086095A5001883769 @default.
• W1998086095 hasAuthorship W1998086095A5017294918 @default.
• W1998086095 hasAuthorship W1998086095A5017760830 @default.
• W1998086095 hasAuthorship W1998086095A5024272482 @default.
• W1998086095 hasAuthorship W1998086095A5030119793 @default.
• W1998086095 hasAuthorship W1998086095A5042156018 @default.
• W1998086095 hasAuthorship W1998086095A5044136579 @default.
• W1998086095 hasAuthorship W1998086095A5048913958 @default.
• W1998086095 hasAuthorship W1998086095A5072416141 @default.
• W1998086095 hasAuthorship W1998086095A5089227561 @default.
• W1998086095 hasAuthorship W1998086095A5089768561 @default.
• W1998086095 hasConcept C101666144 @default.
• W1998086095 hasConcept C126322002 @default.
• W1998086095 hasConcept C12823836 @default.
• W1998086095 hasConcept C13373296 @default.
• W1998086095 hasConcept C134018914 @default.
• W1998086095 hasConcept C164705383 @default.
• W1998086095 hasConcept C203014093 @default.
• W1998086095 hasConcept C206615009 @default.

• next